Poolbeg Pharma makes virus "breakthrough" using AI drug discovery technology

Digital Asset Direct by Poolbeg Pharma PLC

London, UK | November 09, 2022 08:51 AM Eastern Standard Time

Poolbeg Pharma PLC chief executive Jeremy Skillington speaks to Proactive after researchers identified "multiple" potential drug targets for respiratory syncytial virus (RSV) using artificial intelligence. AI technology developed by OneThree Biotech was used to "interrogate" the large bank of RSV human challenge data held by Poolbeg. Skillington says that the breakthrough makes this a "very exciting time for the company" and expects the collaboration to continue bearing fruit.

Contact Details

Proactive

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com